CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 WORLD IN VITRO FERTILIZATION (IVF) MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. IVF PRICING TRENDS BY COUNTRY
3.3. IVF CYCLES BY COUNTRY
3.4. GLOBAL IVF MARKET BY END USERS

3.4.1. Fertility clinics
3.4.2. Hospitals
3.4.3. Surgical centers
3.4.4. Clinical research institutes

3.5. GLOBAL IVF MARKET BY CYCLE TYPE

3.5.1. Fresh IVF cycles (non-donor)
3.5.2. Thawed IVF cycles (non-donor)
3.5.3. Donor egg IVF cycles

3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Delayed pregnancies
3.6.1.2. Rise in global infertility rates
3.6.1.3. Emergence of new fertility tourism destinations

3.6.2. Restraints

3.6.2.1. High Cost involved in the treatment
3.6.2.2. Low level of awareness in developing economies
3.6.2.3. Inadequate reimbursements policies for IVF treatments
3.6.2.4. Ethical Considerations

3.6.3. Opportunities

3.6.3.1. relaxing the legal considerations on ivf treatments
3.6.3.2. New technology development and treatment options
3.6.3.3. Three parent IVF

3.7. KEY FINDINGS

CHAPTER 4 NORTH AMERICA IVF MARKET

4.1. UNITED STATES IVF MARKET, (REVENUE AND NUMBER OF CYCLES)

4.1.1. Number of Infertility Clinics, 2016
4.1.2. United States IVF Market by End Users

4.1.2.1. Fertility clinics
4.1.2.2. Hospitals
4.1.2.3. Surgical centers
4.1.2.4. Clinical research institutes

4.1.3. United States IVF market by cycle type

4.1.3.1. Fresh IVF cycles (non-donor)
4.1.3.2. Thawed IVF cycles (non-donor)
4.1.3.3. Donor egg IVF cycles

4.1.4. Drivers

4.1.4.1. Increasing popularity of IVF in United States
4.1.4.2. Increased rate of infertility and practices of embryo banking cycles

4.1.5. Restraints

4.1.5.1. High cost of IVF treatment in United Sates
4.1.5.2. Restrictions on 3-parent IVF treatments
4.1.5.3. Scattered Reimbursements

4.1.6. Regulatory Issues, Legislations and Authorities
4.1.7. Insurance Reimbursement Scenario
4.1.8. Company Profile

4.1.8.1. Fertility and Gynecology Center Monterey Bay IVF
4.1.8.2. Conceptions Reproductive Associates
4.1.8.3. Servy Massey Fertility Institute
4.1.8.4. Sher Institute for Reproductive Medicine (SIRM)
4.1.8.5. Cardone Reproductive Medicine & Infertility
4.1.8.6. Fertility Center of San Antonio
4.1.8.7. Houston Fertility Center
4.1.8.8. New hope fertility center
4.1.8.9. Reproductive Medicine Associates Of New Jersey

4.2. CANADA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

4.2.1. Number of infertility centers
4.2.2. Canada IVF Market by End users

4.2.2.1. Fertility clinics
4.2.2.2. Hospitals
4.2.2.3. Surgical centers
4.2.2.4. Clinical research institutes

4.2.3. Canada IVF market by cycle type

4.2.3.1. Fresh IVF cycles (non-donor)
4.2.3.2. Thawed IVF cycles (non-donor)
4.2.3.3. Donor egg IVF cycles

4.2.4. Market Dynamics

4.2.4.1. Drivers

4.2.4.1.1. Commercialization of IVF booster in Canada

4.2.4.2. Restraints

4.2.4.2.1. High cost of IVF in Canada

4.2.5. Regulatory Issues, Legislations and Authorities
4.2.6. Insurance Reimbursement Scenario
4.2.7. Company Profile

4.2.7.1. Toronto Centre for Advanced Reproductive Technology Ltd.
4.2.7.2. Fertility Treatment Center
4.2.7.3. Montreal Fertility Center

4.3. MEXICO IVF MARKET (REVENUE AND NUMBER OF CYCLES)

4.3.1. Number of infertility centers
4.3.2. Mexico IVF Market by End Users

4.3.2.1. Fertility clinics
4.3.2.2. Hospitals
4.3.2.3. Surgical centers
4.3.2.4. Clinical research institutes

4.3.3. Mexico IVF market by cycle type

4.3.3.1. Fresh IVF cycles (non-donor)
4.3.3.2. Thawed IVF cycles (non-donor)
4.3.3.3. Donor egg IVF cycles

4.3.4. Market Dynamics

4.3.4.1. Drivers

4.3.4.1.1. Fertility tourism
4.3.4.1.2. Comparatively low cost of IVF

4.3.4.2. Restraints

4.3.4.2.1. Language Barriers

4.3.5. Regulatory Issues, Legislations and Authorities
4.3.6. Insurance Reimbursement Scenario
4.3.7. Company Profile

4.3.7.1. Liv Fertility Center In Puerto Vallarta
4.3.7.2. BFC Biofertility Center

CHAPTER 5 EUROPE IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.1. GERMANY IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.1.1. Number of infertility clinics in Germany
5.1.2. Germany IVF Market by End Users

5.1.2.1. Fertility clinics
5.1.2.2. Hospitals
5.1.2.3. Surgical centers
5.1.2.4. Clinical research institutes

5.1.3. Germany IVF market by cycle type

5.1.3.1. Fresh IVF cycles (non-donor)
5.1.3.2. Thawed IVF cycles (non-donor)

5.1.4. Market Dynamics

5.1.4.1. Drivers

5.1.4.1.1. Subsidizing IVF treatments
5.1.4.1.2. Delayed Marriages and Parenthood decisions

5.1.4.2. Restraints

5.1.4.2.1. Limited adoption of IVF methods

5.1.5. Regulatory Issues, Legislations and Authorities
5.1.6. Insurance Reimbursement Scenario
5.1.7. Company Profile

5.1.7.1. Heidelberg University Hospital
5.1.7.2. Klinikum Stuttgart
5.1.7.3. DRK Kliniken Berlin
5.1.7.4. University Medical Center Freiburg

5.2. FRANCE IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.2.1. Number of infertility centers in France
5.2.2. France IVF Market by End Users

5.2.2.1. Fertility clinics
5.2.2.2. Hospitals
5.2.2.3. Surgical centers
5.2.2.4. Clinical research institutes

5.2.3. France IVF market by cycle type

5.2.3.1. Fresh IVF cycles (non-donor)
5.2.3.2. Thawed IVF cycles (non-donor)
5.2.3.3. Donor egg IVF cycles

5.2.4. Market Dynamics

5.2.4.1. Drivers

5.2.4.1.1. Rising adoption of IVF babies among same gender population
5.2.4.1.2. Lower rates of Fertility

5.2.4.2. Restraints

5.2.4.2.1. Stringent Government regulations

5.2.5. Regulatory Issues, Legislations and Authorities
5.2.6. Insurance Reimbursement Scenario
5.2.7. Company Profile

5.2.7.1. Clinique de la Muette
5.2.7.2. Hopital des metallurgists, hopital cochin

5.3. UNITED KINGDOM IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.3.1. Number of infertility centers in United Kingdom
5.3.2. United Kingdom IVF Market by End Users

5.3.2.1. Fertility clinics
5.3.2.2. Hospitals
5.3.2.3. Surgical centers
5.3.2.4. Clinical research institutes

5.3.3. United Kingdom IVF market by cycle type

5.3.3.1. Fresh IVF cycles (non-donor)
5.3.3.2. Thawed IVF cycles (non-donor)
5.3.3.3. Donor egg IVF cycles

5.3.4. Drivers

5.3.4.1. Commercialization of three-parent IVF procedures
5.3.4.2. Supportive Regulations

5.3.5. Restraints

5.3.5.1. Ethical Considerations

5.3.6. Regulatory Issues, Legislations and Authorities
5.3.7. Insurance Reimbursement Scenario
5.3.8. Company Profile

5.3.8.1. Lister Fertility Clinic
5.3.8.2. The Bridge Center
5.3.8.3. Chelsea and Westminster Hospital (Assisted Conception Unit)

5.4. ITALY IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.4.1. Italy IVF market by End users

5.4.1.1. Fertility clinics
5.4.1.2. Hospitals
5.4.1.3. Surgical centers
5.4.1.4. Clinical research institutes

5.4.2. Italy IVF market by cycle type

5.4.2.1. Fresh IVF cycles (non-donor)
5.4.2.2. Thawed IVF cycles (non-donor)

5.4.3. Market Dynamics

5.4.3.1. Drivers
5.4.3.2. Restraints

5.4.3.2.1. Ban on the Surrogacy

5.4.4. Regulatory issues, legislations and authorities
5.4.5. Insurance Reimbursement Scenario
5.4.6. Company Profile

5.4.6.1. ARC-STER srl
5.4.6.2. RAPRUI
5.4.6.3. Centre for Reproductive Medicine-Napoli

5.5. SPAIN IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.5.1. Spain IVF Market by End Users

5.5.1.1. Fertility clinics
5.5.1.2. Hospitals
5.5.1.3. Surgical centers
5.5.1.4. Clinical research institutes

5.5.2. Spain IVF Market by Cycle Type

5.5.2.1. Fresh IVF cycles (non-donor)
5.5.2.2. Thawed IVF cycles (non-donor)
5.5.2.3. Donor egg IVF cycles

5.5.3. Market Dynamics

5.5.3.1. Drivers

5.5.3.1.1. Increase in the number of foreign patients

5.5.3.2. Restraints

5.5.4. Regulatory Issues, Legislations and Authorities
5.5.5. Insurance Reimbursement Scenario
5.5.6. Company Profiles

5.5.6.1. IVF spain
5.5.6.2. Clnica EUGIN Barcelona

5.6. DENMARK IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.6.1. Denmark IVF Market by End Users

5.6.1.1. Fertility clinics
5.6.1.2. Hospitals
5.6.1.3. Surgical centers
5.6.1.4. Clinical research institutes

5.6.2. Denmark IVF market by cycle type

5.6.2.1. Fresh IVF cycles (non-donor)
5.6.2.2. Thawed IVF cycles (non-donor)
5.6.2.3. Donor egg IVF cycles

5.6.3. Drivers

5.6.3.1. Increase in disposable income
5.6.3.2. Advances in IVF technology

5.6.4. Restraints
5.6.5. Regulatory Issues, Legislations and Authorities
5.6.6. Insurance Reimbursement Scenario
5.6.7. Company Profiles

5.6.7.1. Copenhagen Fertility Center
5.6.7.2. Storkklinik v/Nina Stork
5.6.7.3. Vitanova
5.6.7.4. trianglen fertility clinic
5.6.7.5. Nordica - Denmark, Copenhagen

5.7. RUSSIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.7.1. Russia IVF Market by End Users

5.7.1.1. Fertility clinics
5.7.1.2. Hospitals
5.7.1.3. Surgical centers
5.7.1.4. Clinical research institutes

5.7.2. Russia IVF market by cycle type

5.7.2.1. Fresh IVF cycles (non-donor)
5.7.2.2. Thawed IVF cycles (non-donor)
5.7.2.3. Donor egg IVF cycles

5.7.3. Drivers

5.7.3.1. Rising popularity of fertility tourism

5.7.4. Restraints

5.7.4.1. Inadequate reimbursement policies

5.7.5. Regulatory Issues, Legislations and Authorities
5.7.6. Insurance Reimbursement Scenario
5.7.7. Company Profiles

5.7.7.1. ava-peter clinic
5.7.7.2. MD medical group
5.7.7.3. IVF Russia (The International Centre of the Reproductive Medicines)

5.8. REST OF EUROPE IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.8.1. Rest of Europe IVF Market by End Users

5.8.1.1. Fertility clinics
5.8.1.2. Hospitals
5.8.1.3. Surgical centers
5.8.1.4. Clinical research institutes

5.8.2. Rest of Europe IVF market by cycle type

5.8.2.1. Fresh IVF cycles (non-donor)
5.8.2.2. Thawed IVF cycles (non-donor)
5.8.2.3. Donor egg IVF cycles

5.8.3. Drivers

5.8.3.1. Wide availability of reimbursements
5.8.3.2. Changes in Lifestyle

5.8.4. Restraints
5.8.5. Regulatory Issues, Legislations and Authorities
5.8.6. Insurance Reimbursement Scenario
5.8.7. Company Profiles

5.8.7.1. Gynaecoloqisch Centrum
5.8.7.2. Centrum voor medische genetica
5.8.7.3. Infertility-Vestliitto

CHAPTER 6 ASIA-PACIFIC IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.1. INDIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.1.1. India IVF Market by End Users

6.1.1.1. Fertility clinics
6.1.1.2. Hospitals
6.1.1.3. Surgical centers
6.1.1.4. Clinical research institutes

6.1.2. India IVF market by cycle type

6.1.2.1. Fresh IVF cycles (non-donor)
6.1.2.2. Thawed IVF cycles (non-donor)
6.1.2.3. Donor egg IVF cycles

6.1.3. Market Dynamics

6.1.3.1. Drivers
6.1.3.2. Restraints

6.1.4. Regulatory Issues, Legislations and Authorities
6.1.5. Insurance Reimbursement Scenario
6.1.6. Company Profile

6.1.6.1. Bourn Hall Clinic
6.1.6.2. Southend Fertility and IVF Centre
6.1.6.3. Morpheus IVF Fertility Center
6.1.6.4. Bloom Fertility Center
6.1.6.5. Manipal Ankur
6.1.6.6. Cloudnine
6.1.6.7. Nova IVI Fertility

6.2. CHINA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.2.1. China IVF Market by End User

6.2.1.1. Fertility clinics
6.2.1.2. Hospitals
6.2.1.3. Surgical centers
6.2.1.4. Clinical research institutes

6.2.2. China IVF market by cycle type

6.2.2.1. Fresh IVF cycles (non-donor)
6.2.2.2. Thawed IVF cycles (non-donor)
6.2.2.3. Donor egg IVF cycles

6.2.3. Market Dynamics

6.2.3.1. Drivers

6.2.3.1.1. Change in lifestyle

6.2.3.2. Restraints

6.2.3.2.1. One child policy

6.2.4. Regulatory Issues, Legislations and Authorities
6.2.5. Insurance Reimbursement Scenario
6.2.6. Company profile

6.2.6.1. Reproductive and genetic Hospital Citic-Xiangya
6.2.6.2. Shenyang Hospital
6.2.6.3. Shandong Provincial Hospital
6.2.6.4. Centre for Reproductive Medicine

6.3. JAPAN IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.3.1. Japan IVF Market by End-Users

6.3.1.1. Fertility clinics
6.3.1.2. Hospitals
6.3.1.3. Surgical centers
6.3.1.4. Clinical research institutes

6.3.2. Japan IVF market by cycle type

6.3.2.1. Fresh IVF cycles (non-donor)
6.3.2.2. Thawed IVF cycles (non-donor)

6.3.3. Market Dynamics

6.3.3.1. Drivers
6.3.3.2. Restraints

6.3.4. Regulatory Issues, Legislations and Authorities
6.3.5. Insurance Reimbursement Scenario
6.3.6. Company Profile

6.3.6.1. EMD Serono, Inc
6.3.6.2. IVF NAMBA Clinic
6.3.6.3. Iwaki Womens Clinic
6.3.6.4. Sanno Hospital

6.4. AUSTRALIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.4.1. Australia IVF Market by End Users

6.4.1.1. Fertility clinics
6.4.1.2. Hospitals
6.4.1.3. Surgical centers
6.4.1.4. Clinical research institutes

6.4.2. Australia IVF market by cycle type

6.4.2.1. Fresh IVF cycles (non-donor)
6.4.2.2. Thawed IVF cycles (non-donor)

6.4.3. Market Dynamics

6.4.3.1. Drivers
6.4.3.2. Restraints

6.4.3.2.1. Emotional and physical stress
6.4.3.2.2. No guarantee for the successful treatments
6.4.3.2.3. Surplus embryos

6.4.4. Regulatory Issues, Legislations and Authorities
6.4.5. Insurance Reimbursement Scenario
6.4.6. Company Profile

6.4.6.1. Genea Biomedx
6.4.6.2. Thermo Fisher Scientific Inc.
6.4.6.3. Virtus Health limited
6.4.6.4. Monash IVF
6.4.6.5. City Fertility center, brisbane
6.4.6.6. Flinders Fertility clinic

6.5. NEW ZEALAND IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.5.1. New Zealand IVF Market by End users

6.5.1.1. Fertility clinics
6.5.1.2. Hospitals
6.5.1.3. Surgical centers
6.5.1.4. Clinical research institutes

6.5.2. New Zealand IVF Market by Cycle Type

6.5.2.1. Fresh IVF cycles (non-donor)
6.5.2.2. Thawed IVF cycles (non-donor)
6.5.2.3. Donor egg IVF cycles

6.5.3. Market Dynamics

6.5.3.1. Drivers
6.5.3.2. Restraints

6.5.4. Regulatory Issues, Legislations and Authorities
6.5.5. Insurance Reimbursement Scenario
6.5.6. Company Profiles

6.5.6.1. Fertility Associates
6.5.6.2. Fertility Plus
6.5.6.3. Repromed

6.6. KOREA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.6.1. Korea IVF Market by End Users

6.6.1.1. Fertility clinics
6.6.1.2. Hospitals
6.6.1.3. Surgical centers
6.6.1.4. Clinical research institutes

6.6.2. Korea IVF market by cycle type

6.6.2.1. Fresh IVF cycles (non-donor)
6.6.2.2. Thawed IVF cycles (non-donor)
6.6.2.3. Donor egg IVF cycles

6.6.3. Market Dynamics

6.6.3.1. Drivers
6.6.3.2. Restraints

6.6.4. Regulatory Issues, legislations and Authorities
6.6.5. Insurance Reimbursement Scenario
6.6.6. Company Profiles

6.6.6.1. Cha General Hospital
6.6.6.2. MARIA Fertility Hospital

6.7. THAILAND IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.7.1. Thailand IVF Market by End Users

6.7.1.1. Fertility clinics
6.7.1.2. Hospitals
6.7.1.3. Surgical centers
6.7.1.4. Clinical research institutes

6.7.2. Thailand IVF market by cycle type

6.7.2.1. Fresh IVF cycles (non-donor)
6.7.2.2. Thawed IVF cycles (non-donor)
6.7.2.3. Market Dynamics
6.7.2.4. Drivers

6.7.2.4.1. Government initiatives
6.7.2.4.2. Economic considerations
6.7.2.4.3. Boost in medical tourism

6.7.2.5. Restraints

6.7.2.5.1. Comparatively low success rate
6.7.2.5.2. Ethical issues in allowing gender selection

6.7.3. Regulatory Issues, legislations and Authorities
6.7.4. Insurance Reimbursement Scenario
6.7.5. Company Profiles

6.7.5.1. Bangkok Fertility Center
6.7.5.2. Siriraj Hospital
6.7.5.3. Ramathibodi Hospital
6.7.5.4. Perfect Woman Institute
6.7.5.5. Jetanin Institute for Assisted Reproduction

6.8. OTHER ASIA-PACIFIC IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.8.1. Other Asia-Pacific IVF Market by End Users

6.8.1.1. Fertility clinics
6.8.1.2. Hospitals
6.8.1.3. Surgical centers
6.8.1.4. Clinical research institutes

6.8.2. Other Asia-Pacific IVF market by cycle type

6.8.2.1. Fresh IVF cycles (non-donor)
6.8.2.2. Thawed IVF cycles (non-donor)
6.8.2.3. Donor egg IVF cycles

6.8.3. Drivers

6.8.3.1. Increase in disposable income
6.8.3.2. Advances in IVF technology
6.8.3.3. Decline in fertility rate

6.8.4. Restraints

6.8.4.1. Physical and emotional impact due to low success rate

6.8.5. Regulatory Issues, legislations and Authorities
6.8.6. Insurance Reimbursement Scenario
6.8.7. Company Profiles

6.8.7.1. Fertility Centre, Siloam Hospitals Surabana
6.8.7.2. CRM-MIA-Philippines
6.8.7.3. IVFAS

CHAPTER 7 LAMEA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

7.1. LATIN AMERICA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

7.1.1. Number of Infertility Centers
7.1.2. Latin America IVF Market by End users

7.1.2.1. Fertility clinics
7.1.2.2. Hospitals
7.1.2.3. Surgical centers
7.1.2.4. Clinical research institutes

7.1.3. Latin America IVF market by cycle type

7.1.3.1. Fresh IVF cycles (non-donor)
7.1.3.2. Thawed IVF cycles (non-donor)
7.1.3.3. Donor egg IVF cycles

7.1.4. Drivers

7.1.4.1. Rising Medical Tourism in Latin American Countries
7.1.4.2. Permission for IVF treatments in Costa Rica

7.1.5. Restraints

7.1.5.1. High infant mortality rates in Brazil

7.1.6. Regulatory Issues, legislations and Authorities
7.1.7. Insurance Reimbursement Scenario
7.1.8. Profiles of Major Players

7.1.8.1. Clinica Anglo Americana
7.1.8.2. IVF Panama Centro De Reproduccion
7.1.8.3. Insemer
7.1.8.4. Almater Hospital
7.1.8.5. San Fernando Hospital

7.2. MIDDLE EAST IVF MARKET (REVENUE AND NUMBER OF CYCLES)

7.2.1. Number of infertility centers
7.2.2. Middle East IVF Market by End users

7.2.2.1. Fertility clinics
7.2.2.2. Hospitals
7.2.2.3. Surgical centers
7.2.2.4. Clinical research institutes

7.2.3. Middle East IVF market by Cycle Type

7.2.3.1. Fresh IVF cycles (non-donor)
7.2.3.2. Thawed IVF cycles (non-donor)
7.2.3.3. Donor egg IVF cycles

7.2.4. Market Dynamics

7.2.4.1. Drivers

7.2.4.1.1. High-tech culture in the Middle East countries
7.2.4.1.2. Availability of Reimbursements

7.2.4.2. Restraints

7.2.4.2.1. Stringent government regulations in Middle East Regions

7.2.5. Regulatory Issues, Legislations and Authorities
7.2.6. Insurance Reimbursement Scenario
7.2.7. Company Profile

7.2.7.1. Cyprus IVF Centre
7.2.7.2. Al Bushra Medical Specialty Complex
7.2.7.3. Reproductive Medicine Unit at Corniche Hospital (Corniche Fertility center)
7.2.7.4. Trakya University Hospital ART Center

7.3. AFRICA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

7.3.1. Number of infertility centers
7.3.2. Africa IVF Market by End users

7.3.2.1. Fertility clinics
7.3.2.2. Hospitals
7.3.2.3. Surgical centers
7.3.2.4. Clinical research institutes

7.3.3. Africa IVF market by Cycle Type

7.3.3.1. Fresh IVF cycles (non-donor)
7.3.3.2. Thawed IVF cycles (non-donor)
7.3.3.3. Donor egg IVF cycles

7.3.4. Drivers

7.3.4.1. Low costs of IVF treatment
7.3.4.2. Rising Fertility Tourism in South Africa

7.3.5. Restraints

7.3.5.1. Susceptibility toward fibroids

7.3.6. Regulatory Issues, legislations and Authorities
7.3.7. Insurance Reimbursement Scenario
7.3.8. Company Profile

7.3.8.1. Lifesure Fertility & Gynaecology Centre
7.3.8.2. Bethany Women and Family Hospital
7.3.8.3. BioART Fertility Centre
7.3.8.4. DEL International Hospital & Fertility Centre
7.3.8.5. Gift ov life
7.3.8.6. Durban Fertility Clinic
7.3.8.7. Cape fertility clinic